[go: up one dir, main page]

WO1996020950A3 - Compositions et therapies pour le traitement de la polyarthrite rhumatoide - Google Patents

Compositions et therapies pour le traitement de la polyarthrite rhumatoide Download PDF

Info

Publication number
WO1996020950A3
WO1996020950A3 PCT/US1996/000206 US9600206W WO9620950A3 WO 1996020950 A3 WO1996020950 A3 WO 1996020950A3 US 9600206 W US9600206 W US 9600206W WO 9620950 A3 WO9620950 A3 WO 9620950A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
rheumatoid arthritis
methods
compositions
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/000206
Other languages
English (en)
Other versions
WO1996020950A2 (fr
Inventor
Jonathan Rothbard
Lars Henrik Fugger
Grete Sonderstrup-Mcdevitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Priority to AU46952/96A priority Critical patent/AU4695296A/en
Publication of WO1996020950A2 publication Critical patent/WO1996020950A2/fr
Publication of WO1996020950A3 publication Critical patent/WO1996020950A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des peptides, des compositions thérapeutiques et des thérapies pour le traitement de la polyarthrite rhumatoïde chez des mammifères, en particulier chez les humains. Les peptides de l'invention comprennent des fragments de collagène du type II se fixant spécifiquement aux protéines du complexe majeur d'histocompatibilité humain, qui sont connues pour être génétiquement liées à une prédisposition à la polyarthrite rhumatoïde. Les compositions thérapeutiques de l'invention comprennent ces peptides, seuls ou en combinaison avec d'autres peptides du collagène. Dans une thérapie selon l'invention, les compositions thérapeutiques de peptides sont administrées à un patient nécessitant une telle thérapie, par injection, par voie transdermale, par inhalation ou par voie orale.
PCT/US1996/000206 1995-01-06 1996-01-04 Compositions et therapies pour le traitement de la polyarthrite rhumatoide Ceased WO1996020950A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46952/96A AU4695296A (en) 1995-01-06 1996-01-04 Compositions and methods for treating rheumatoid arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36979295A 1995-01-06 1995-01-06
US08/369,792 1995-01-06

Publications (2)

Publication Number Publication Date
WO1996020950A2 WO1996020950A2 (fr) 1996-07-11
WO1996020950A3 true WO1996020950A3 (fr) 1996-09-12

Family

ID=23456941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000206 Ceased WO1996020950A2 (fr) 1995-01-06 1996-01-04 Compositions et therapies pour le traitement de la polyarthrite rhumatoide

Country Status (2)

Country Link
AU (1) AU4695296A (fr)
WO (1) WO1996020950A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
SE9700301D0 (sv) * 1997-01-31 1997-01-31 Astra Ab New compound
AUPO571297A0 (en) * 1997-03-19 1997-04-10 Montech Medical Developments Pty Ltd Method for the diagnosis of rheumatoid arthritis
EP1598370A3 (fr) * 1999-10-27 2006-05-10 Cel-Sci Corporation Möthodes de préparation et composition de constructions peptidiques utiles dans le traitement d'etats auto-immunes et de greffes liées à la réaction du greffon contre l'hôte
WO2003006603A2 (fr) * 2001-07-12 2003-01-23 Arexis Ab Complexes triple de polypeptides
NZ546807A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2010054446A1 (fr) 2008-11-11 2010-05-20 Ademovic Zlatko Combinaison de deux peptides ou plus dans un composé pharmaceutique unique lyophilisé et stable
EP2694530B1 (fr) * 2011-04-05 2018-02-14 Curara AB Nouveaux peptides qui se lient à des types de cmh (complexe majeur d'histocompatibilité) de classe ii et leur utilisation en vue de diagnostic et de traitement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007520A1 (fr) * 1992-09-25 1994-04-14 Autoimmune, Inc. Procede de traitement de la polyarthrite rhumatoide avec du collagene de type ii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007520A1 (fr) * 1992-09-25 1994-04-14 Autoimmune, Inc. Procede de traitement de la polyarthrite rhumatoide avec du collagene de type ii

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E.MICHAELSSON ET AL: "Identification of an immunodominant Type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection", EUR.J.IMMUNOL., vol. 22, no. 7, 1992, pages 1819 - 25, XP002006497 *
L.K.MYERS ET AL.: "A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen- induced arthritis", J.IMMUNOL., vol. 150, no. 10, 1993, pages 4652 - 8, XP002006498 *

Also Published As

Publication number Publication date
WO1996020950A2 (fr) 1996-07-11
AU4695296A (en) 1996-07-24

Similar Documents

Publication Publication Date Title
GR3035440T3 (en) Therapeutic uses of bpi protein products for human meningococcemia
WO1998026747A3 (fr) Procedes et compositions de traitement de maladies a base de superantigenes
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
HUT74832A (en) Method and compositions for treatment of autoimmune diseases by use of bystander antigen
EP0853121A3 (fr) DNase humaine
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
WO1996020950A3 (fr) Compositions et therapies pour le traitement de la polyarthrite rhumatoide
ZA917957B (en) Delivery of therapeutic agents using modified antibody fragments.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
EP0321094A3 (fr) Traitement des inhibiteurs de facteur VIII
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DE59805440D1 (de) Verwendung von lbp zur sepsistherapie
WO2003059334A3 (fr) Gemcitabine pour traiter la variole
MX9706429A (es) Variantes de dnasa i humana.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA